To include your compound in the COVID-19 Resource Center, submit it here.

FDA panel votes against J&J's sirukumab approval in RA

FDA's Arthritis Advisory Committee (AAC) voted 12-1 against approval of sirukumab (CNTO 136) from Johnson & Johnson (NYSE:JNJ) to treat moderately to severely

Read the full 231 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE